ARCHIVES

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

This article is from The Cancer Letter archive.

Vol. 30 No. 16 | April 16, 2004

Download PDF Visit The Full Archive

Related Articles

NCI New Advisory Group Named On special Populations

June 25, 1999

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

May 8, 1987

DCT Board Approves Continuing Neutron Trials Pas 1989 Expiration, With New Funding Plan

June 10, 1988

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

February 24, 1995

ImClone: Waksals To Pay $5 Million To Settle With SEC.

January 28, 2005

Large, Conclusive Trials Provide Answers To Treatment Questions For GI Cancers

June 26, 2009